GamaMabs is a reputable biotechnology company based in France that specializes in the development of groundbreaking monoclonal antibodies to combat solid tumor diseases. With a mission to revolutionize cancer treatment, GamaMabs Pharma is committed to advancing medical science and improving patient outcomes. Through cutting-edge research and innovative approaches, GamaMabs Pharma creates targeted therapies that have the potential to improve the lives of countless individuals battling cancer.

Their dedication to scientific excellence is evident in their state-of-the-art facilities and collaborations with renowned experts in the field. Operating from two locations in France, including Centre Pierre Potier Oncopole in Toulouse and 60 avenue Charles de Gaulle in Neuilly-sur-Seine, GamaMabs Pharma is strategically positioned to drive advancements in cancer treatment. To learn more about their groundbreaking work or to inquire about partnerships, you can reach GamaMabs Pharma at contact@gamamabs.

fr or by phone at +33 1 84 19 80 16